The University Of Texas Health Science Center At Tyler

The University Of Texas Health Science Center At Tyler, a state-controlled academic health center and component of the University of Texas System headquartered in Tyler, Texas, operates as a prime recipient of federal grants and a prime contractor for specialized microbiology laboratory services and clinical research, competing predominantly in full-and-open federal grant programs rather than set-asides. The institution does not hold positions on government-wide acquisition vehicles or schedules.

The institution's federal footprint centers on biomedical and infectious disease research grounded in NIH grant awards and specialized clinical laboratory services for the Department of Veterans Affairs. Research capability spans respiratory infectious disease (nontuberculous mycobacteria, tuberculosis, influenza), immunological mechanisms in infectious and inflammatory disease, hemostasis and coagulation disorders, and environmental health determinants following natural disasters. Clinical laboratory work focuses on microbiology reference testing and susceptibility assays. Representative prime grant awards include a $223,500 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855) to investigate RUNX3 as a therapeutic target for primary hemophagocytic lymphohistiocytosis (July 2026 through June 2028), a $287,516 Project Grant from the National Science Foundation Division of Environmental Biology (CFDA 47.074) investigating cyclone-induced flooding and nontuberculous mycobacterial emergence in Hawaii (July 2026 through June 2027), and a $249,000 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837) examining lipid peroxidation and pyroptosis-induced tissue factor activation in pathogen-induced blood coagulation (June 2026 through April 2029). Prime contract work includes a single-award Indefinite Delivery Contract with Veterans Integrated Service Network 17 (VA North Texas Health Care System) with a $75,000 ceiling running through August 2029, under which three delivery orders totaling approximately $32,180 have been issued for microbiology reference laboratory services performed in Tyler, Texas.

Customer concentration is dominated by the National Institutes of Health. The top five funding agencies account for 49% of recent awards: the National Institutes of Health (29 awards), the National Heart, Lung, and Blood Institute (24 awards, a NIH component), the National Institute of Allergy and Infectious Diseases (21 awards, a NIH component), the Department of Veterans Affairs (13 awards), and Veterans Integrated Service Network 17 (7 awards, $121 thousand combined potential value). By potential value, the Veterans Administration leads at $121 thousand across 7 awards, followed by the Department of Labor at $110 thousand across 8 awards combined (Office of the Assistant Secretary for Administration and Management and Occupational Safety and Health Administration). The disparity between award count and dollar ranking reflects the grant-dominated portfolio: NIH grants carry lower individual values than VA delivery orders on clinical laboratory contracts.

Recent activity shows growth from 11 awards in 2022 to 24 in 2024, declining to 15 in 2025 and 9 so far in 2026, reflecting the timing of grant cycles and annual contract reorders. Sixteen awards with ultimate completion in the next twenty-four months carry combined potential value of $28 thousand, representing modest recompete exposure. The institution holds a position on two IDIQs: Indefinite Delivery Contract V549P4737 (12 task orders) and Indefinite Delivery Contract 36C25724D0066 (3 task orders, $32 thousand combined potential value).

The institution serves as a sub-recipient on multiple NIH-funded grant programs, with recent sub-award work performed under primes including Oregon Health & Science University (nontuberculous mycobacterium clinical trials and diagnostic research), the Texas Biomedical Research Institute (Interdisciplinary NexGen TB research advancement), the University of Texas Health Science Center at Houston (cardiovascular research and COVID-19 testing disparities), the University of Florida (nanoparticle pharmacokinetics research), the Texas A&M Transportation Institute (rural road safety), and the Department of State Health Services (perinatal quality, public health laboratory workforce, and chronic disease prevention). A single federal contract sub-award appears in the source: a December 2023 sub-award from Medical Science & Computing, LLC for preclinical services under the NHLBI Catalyze Program.

The institution's NAICS portfolio reflects its mission: Medical Laboratories (15 awards), HMO Medical Centers (7 awards), and Research and Development in the Physical, Engineering, and Life Sciences (5 awards). PSC codes align: Medical-Managed Healthcare (13 awards), Reference Laboratory Testing (9 awards), and In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (6 awards).